Hospital Mater Dei (MATD3) investor relations material

Executive summary

• Achieved record consolidated net revenue of BRL 614 million in Q2 2026, up 12.4% year-over-year, driven by higher average ticket, strong performance in oncology and high-complexity services, and improved specialty mix.

• Adjusted EBITDA grew 20.3% year-over-year to BRL 139 million, with margin rising to 22.6%, and net income increased 66.1% to BRL 45 million.

• Operational efficiency gains included occupancy rates near 84%, increased patient-days, and disciplined bed expansion.

• Expansion and maturation of newer units, notably Salvador (30% revenue growth, 133% increase in oncology patients) and Nova Lima (84% net revenue growth, 25% more oncology patients), contributed to overall results.

• Strengthened partnerships and new accreditations, including Bradesco Efetivo Plus in Salvador, enhanced market positioning and access to new beneficiaries.

Financial highlights

• Net revenue reached BRL 614 million, a 12.4% increase year-over-year and 6.7% sequential growth.

• Adjusted EBITDA was BRL 139 million, up 20.3% year-over-year, with margin at 22.6%.

• Adjusted net profit rose 66.1% to BRL 45 million, with net margin up 2.3pp to 7.3%.

• Gross profit for 2Q26 was BRL 186.7 million (+13.3% YoY), with gross margin at 30.4%.

• Net debt reduced by BRL 37 million to BRL 763 million, with leverage ratio improving to 1.5x EBITDA.

Outlook and guidance

• Optimistic outlook for H2 2026, expecting further volume growth from new teams, partnerships, and increased business days.

• Continued focus on operational efficiency, specialty mix, cost control, and expansion in Bahia and other regions.

• Strategy emphasizes strengthening regional corporate market presence through partnerships and accreditations.